Viridian Therapeutics

Business news, market intelligence, and global industry analysis.

The Latest

Representative image of premium spirits bottles and market screens illustrating the Pernod Ricard SA and Brown-Forman Corporation merger talks that could reshape the global spirits industry.

Pernod Ricard and Brown-Forman confirm merger talks that could reshape the global spirits industry

Judge blocks Pentagon from blacklisting Anthropic: ‘Classic First Amendment retaliation’

Catapult Sports (ASX: CAT) posts record 27-28% ACV growth in FY26 trading update as dual acquisitions reshape the sports analytics platform

Representative image of a laboratory skin research setting illustrating the kind of translational science behind Rubedo Life Sciences’ RLS-1496 Phase 1 dermatology results in psoriasis, atopic dermatitis, and skin aging.

Aging biotech just got a real skin test and Rubedo Life Sciences may have passed the first one

Viridian Therapeutics reports 70% durability at one year in Phase 3 THRIVE trial for veligrotug in thyroid eye disease

Viridian's veligrotug maintained a 70% response at 52 weeks in TED patients; BLA filing expected in H2 2025. Find out how this breakthrough could reshape care.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

May 20, 2025